Short radiation then chemotherapy for locally advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed rectal adenocarcinoma confirmed by biopsy (no prior cancer treatment).
- Your cancer is stage T3–4 and/or involves nearby lymph nodes (N+), and it can be surgically removed, located within 12 cm of the anus.
- You are age 18 to 70, and you can take part if you are male or a non-pregnant female.
- Your blood counts are high enough (white blood cells, neutrophils, platelets, and hemoglobin).
- Your kidneys and liver are working well enough for chemotherapy (based on lab tests).
- You are able to complete all planned study treatments and do not have serious uncontrolled heart/lung/brain problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a shorter course of radiation before chemotherapy and an immunotherapy drug to shrink mid-to-lower rectal cancer that has not spread. The goal is to improve treatment response and reduce side effects, potentially allowing for less invasive surgery.
This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
Hear when a new Radiation Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.